Recommendations for Use of Video Directly Observed Therapy During Tuberculosis Treatment — United States, 2023
Joan M. Mangan, Rachel S. Woodruff, Carla A. Winston, Scott A. Nabity, Maryam B. Haddad, Meredith G. Dixon, Farah M. Parvez, Carissa Sera-Josef, LaTweika A.T. Salmon-Trejo, Chee Kin Lam
Abstract
U.S. clinical practice guidelines recommend directly observed therapy (DOT) as the standard of care for tuberculosis (TB) treatment (1). DOT, during which a health care worker observes a patient ingesting the TB medications, has typically been conducted in person. Video DOT (vDOT) uses video-enabled devices to facilitate remote interactions between patients and health care workers to promote medication adherence and clinical monitoring. Published systematic reviews, a published meta-analysis, and a literature search through 2022 demonstrate that vDOT is associated with a higher proportion of medication doses being observed and similar proportions of cases with treatment completion and microbiologic resolution when compared with in-person DOT (2-5). Based on this evidence, CDC has updated the recommendation for DOT during TB treatment to include vDOT as an equivalent alternative to in-person DOT. vDOT can assist health department TB programs meet the U.S. standard of care for patients undergoing TB treatment, while using resources efficiently.